טוען...
The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma
INTRODUCTION: In the era of precision medicine and sophisticated modern genetics, the discovery of the BRAF(V600) inhibitor, vemurafenib, quickly became the model for targeted therapy in melanomas. As early as 2002, the majority of metastatic melanomas were described to harbor the BRAF(V600) mutatio...
שמור ב:
| הוצא לאור ב: | Expert Opin Drug Discov |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5443413/ https://ncbi.nlm.nih.gov/pubmed/27327499 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/17460441.2016.1201057 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|